Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TransMedics Group, Inc. (NASDAQ: TMDX), a leader in portable organ transplantation technology, announced its Q1 2023 financial results release scheduled for May 1, 2023, after market close. A conference call will follow at 4:30 p.m. ET. TransMedics focuses on improving organ quality and viability assessment, aiming to increase donor organ utilization for patients facing end-stage lung, heart, and liver failure. The company is headquartered in Andover, Massachusetts, and its technologies are crucial in addressing the significant need for better organ transplant solutions.